1 / 76

Kia Ora!

Kia Ora!. Cohort Event Monitoring Prescription event monitoring (PEM). Dr. David Coulter formerly Research Associate Professor Intensive Medicines Monitoring Programme & Head NZ Pharmacovigilance Centre Dr. Geraldine Hill

fleur
Télécharger la présentation

Kia Ora!

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Kia Ora!

  2. Cohort Event MonitoringPrescription event monitoring (PEM) Dr. David Coulter formerly Research Associate Professor Intensive Medicines Monitoring Programme & Head NZ Pharmacovigilance Centre Dr. Geraldine Hill Teaching Fellow, University of Otago Medical School, Dunedin, New Zealand (formerly Research Fellow Intensive Medicines Monitoring Programme) Tanzania

  3. CEM worldwide • NZ Intensive Medicines Monitoring Programme (IMMP), NZ, 1977 • Drug Safety Research Unit (PEM), Southampton, UK, 1980 • Tanzania CEM of anti-malarials • Nigeria

  4. Plan of presentation • Objectives • What results can you get? Examples and methods from the NZ Intensive Medicines Monitoring Programme (IMMP) • How do we get them? • Observations & comments

  5. The objectives of CEM • Characterise known reactions • Mean age • Gender • Mean dose • Treatment duration • Time to onset • Seriousness profile • Incidence • Outcomes • Effect on treatment (% withdrawals) • Part of syndrome?

  6. The objectives of CEM • Detect signals of unrecognised reactions • Interactions with • Other medicines • Complementary and alternative medicines • Foods • Identify risk factors so that they can be avoided Age Duration of therapy Gender Concomitant disease Dose Concomitant therapy

  7. The objectives of CEM • Assess safety in pregnancy & lactation • Estimate risk (including comparative) • Provide evidence for effective risk management • Safer prescribing • Benefit / harm assessment • Regulatory changes

  8. The objectives of CEM • Detect inefficacy, which might be due to • Faulty administration • Poor storage conditions • Out of date • Poor quality product • Counterfeit • Interactions

  9. The objectives of CEM • Hypothesis generation • Cohorts for study

  10. The objectives Achieve maximum benefit, least harmfor patients

  11. What results can you get?

  12. COX-2 inhibitorscelecoxib, rofecoxib Preliminary monitoring data

  13. The following will be summarised • Cohort description & drug utilisation • Preliminary events data • Preliminary review of deaths

  14. IMMP Process Prescription Patient and Prescription details Follow-up questionnaires Event information Cohort data Relationship assessment NZHIS

  15. Cohort

  16. IMMP example –COX-2

  17. Gender and term

  18. Rofecoxib dose mg/day No. %

  19. Celecoxib dose mg/no./%

  20. IMMP Process Prescription Patient and Prescription details Follow-up questionnaires Event information Cohort data Relationship assessment NZHIS

  21. Indications for use(0r type/seriousness of malaria)

  22. Baseline information 1 Questions • Current Acid Related Disorder • Past ARD • NSAID exposure • Past GI problems • Direct switch to COX-2 • Concurrent aspirin • Past cardiovascular disease • Hypertension / Heart failure • MI / Angina • Dysrhythmia / Stroke - TIA

  23. Baseline information 2 Questionnaire response rate • Celecoxib: number sent 4635 • No. returned with information 3985 (91%) • Rofecoxib: number sent 3050 • No. returned with information 2725 (89%)

  24. Baseline information 3No. & % of positive responses to question

  25. Baseline information 4Cardiovascular disease

  26. The events

  27. Most common events 1rates /1000 patients

  28. Most common events 2

  29. Most common events 3

  30. Signals identified 1 • Coughing • Visual field defect / temp blindness • Acute psychiatric events • Pancreatitis • Hepatotoxicity • Psoriasis • Acute urinary retention

  31. Signals 2 • Mouth ulceration • Lower bowel effects • Cardiac dysrhythmias • Cardiac arrest • Myocardial infarction / stroke • Anaphylaxis • Serious skin infection • Acute labyrinthitis

  32. Signals 3 Interactions • Tricyclics causing arrhythmias • Warfarin causing increased INR (rofecoxib)

  33. DeathsCauses by SOC (% of total deaths)

  34. Risk factors 1 • by multiple logistic regression • Renal failure • Age • Inflammatory arthritis • Heart failure • Age • P/H heart failure • Inflammatory arthritis

  35. Risk factors 2 • Ischaemic heart disease • Age • P/H of any type of heart disease • Inflammatory arthritis (celecoxib) • Cardiac dysrhythmias • Age • Past history of heart failure • Inflammatory arthritis (celecoxib)

  36. Risk factors 3 • Stroke / TIA • Age • Hypertension • Inflammatory arthritis

  37. Did we reach the objectives?

  38. Study demonstrates • High compliance • Demographics of cohorts • Background data • Indication • Relevant past/current history • Prescribing practices • Early signal identification • Significant events • Comparative rates • Risk factors

  39. Concerns raised • High volume of prescribing • High doses of rofecoxib • Substantial prescribing to patients at high risk • very elderly • history of cardiovascular disease • history of ARD • Apparent high death rate

  40. Concerns • High rate of cardiovascular events • Heart failure • Dysrhythmias • Prothrombotic effects • Myocardial infarction • Stroke • Renal infarction • High rate of alimentary events

  41. How do we get results like this? The principles

  42. Cohort event monitoringHow is it done? Two Principles • Identifying patients exposed (cohort) - the denominator • as complete as possible • Systematically soliciting adverse EVENTS - the numerator • as complete as possible

  43. 1. Identifying the patients How can this be done? • The cohort of patients is established using the best source of usage data available • Dispensings (pharmacies or central records) • Patient records • Doctors • Clinics • Hospitals • Other • Programme records • Adequate cohort (10,000 patients)

  44. IMMP Process Prescription Patient and Prescription details Follow-up questionnaires Event information Other Rx Sources Cohort data Relationship assessment NZHIS

  45. Cohort size • General aim 10,000 (IMMP 11,000) • Greater numbers required to detect differences • if events naturally common • for sub-group analyses • Smaller numbers still produce good data • fluoxetine <7000 • Signals can be identified / confirmed with much smaller numbers (<1000) • eg nifedipine & eye pain

  46. 2. Soliciting the eventsHow can this be done? • Activelyasking for the events • Systematicallyasking for the events

  47. Soliciting the eventsHow is it done? • The events are collected using the best source(s) available • Survey prescribers (questionnaires or other) • Survey patients (questionnaires or other) • Real-time recording* • Telephone, or visit* • Record searches (manual, electronic) • Registers of death or morbidity • Record linkage with registers or hospital records • Intensified spontaneous reporting • Other • Several

  48. IMMP Process Prescription Patient and Prescription details Follow-up questionnaires Event information Other Rx Sources Cohort data Relationship assessment Other Sources NZHIS

More Related